Phase I Study of Colchicine Therapy in Childhood Hepatic Cirrhosis

National Center for Research Resources (NCRR)15 enrolled

Overview

OBJECTIVES: I. Investigate the efficacy and safety of colchicine therapy in improving hepatic function and reducing hepatic fibrosis (scarring) in children with hepatic cirrhosis.

PROTOCOL OUTLINE: Patients receive colchicine orally twice daily for 24 months. After the first month, the dose of colchicine will increase and remain at that dose for the duration of study. Patients are evaluated every 6 months during study.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Enrollment

Conditions

Cirrhosis Liver Cirrhosis

Interventions

colchicineDRUG

Eligibility

Sex: ALLMin age: 0 YearsMax age: 17 Years

Medical Language ↔ Plain English

* Advanced hepatic fibrosis or cirrhosis in children * Not pregnant

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.